Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1984 1
1988 2
1989 1
1990 3
1991 2
1994 3
1995 4
1996 4
1998 2
1999 1
2003 3
2004 3
2005 6
2006 7
2007 6
2008 6
2009 8
2010 6
2011 16
2012 11
2013 8
2014 8
2015 11
2016 13
2017 13
2018 12
2019 10
2020 13
2021 6
2022 8
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H. Sardar M, et al. Among authors: mahadevan d. Expert Opin Pharmacother. 2022 Dec;23(18):2079-2089. doi: 10.1080/14656566.2022.2149322. Epub 2022 Nov 28. Expert Opin Pharmacother. 2022. PMID: 36394449 Review.
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages.
Hung CN, Chen M, DeArmond DT, Chiu CH, Limboy CA, Tan X, Kusi M, Chou CW, Lin LL, Zhang Z, Wang CM, Chen CL, Mitsuya K, Osmulski PA, Gaczynska ME, Kirma NB, Vadlamudi RK, Gibbons DL, Warner S, Brenner AJ, Mahadevan D, Michalek JE, Huang TH, Taverna JA. Hung CN, et al. Among authors: mahadevan d. Cell Rep. 2023 Sep 26;42(9):113067. doi: 10.1016/j.celrep.2023.113067. Epub 2023 Sep 1. Cell Rep. 2023. PMID: 37659081 Free PMC article.
A call to arms: Unifying the fight against resistance.
Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA. Kaushansky A, et al. Among authors: mahadevan d. Sci Signal. 2018 Oct 23;11(553):eaav0442. doi: 10.1126/scisignal.aav0442. Sci Signal. 2018. PMID: 30352947 Free PMC article.
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S, Babiker HM, Mahadevan D. Chandana S, et al. Among authors: mahadevan d. Expert Opin Investig Drugs. 2019 Feb;28(2):161-177. doi: 10.1080/13543784.2019.1557145. Epub 2018 Dec 16. Expert Opin Investig Drugs. 2019. PMID: 30539678 Review.
Quo vadis, foot & ankle research? A review.
Krause F, Herrera M, Walcher M, Mahadevan D, Michels F. Krause F, et al. Among authors: mahadevan d. Foot Ankle Surg. 2023 Oct;29(7):502-505. doi: 10.1016/j.fas.2023.08.003. Epub 2023 Aug 19. Foot Ankle Surg. 2023. PMID: 37648639 Review.
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
Fakih M, Harb W, Mahadevan D, Babiker H, Berlin J, Lillie T, Krige D, Carter J, Cox C, Patel M, Parfitt L, Powell M, Rosen L. Fakih M, et al. Among authors: mahadevan d. J Immunother Cancer. 2023 Apr;11(4):e006561. doi: 10.1136/jitc-2022-006561. J Immunother Cancer. 2023. PMID: 37094988 Free PMC article. Clinical Trial.
Novel therapeutics for aggressive non-Hodgkin's lymphoma.
Mahadevan D, Fisher RI. Mahadevan D, et al. J Clin Oncol. 2011 May 10;29(14):1876-84. doi: 10.1200/JCO.2010.32.7171. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483007 Free PMC article. Review.
181 results